22 October 2025 - Australians with the extremely rare and life-threatening inherited disease, acid sphingomyelinase deficiency (ASMD) will now have free access to a life saving medicine.

Olipudase alfa (Xenpozyme), an enzyme replacement therapy, will be listed on the LSDP as the first and only effective treatment approved for Australians with ASMD in children and adult patients with type A/B (Niemann-Pick type A/B) or type B (Niemann-Pick type B).

Read Minister for Health press release